Cargando…

Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?

OBJECTIVE: To determine whether increased elimination of gadobenate ion via the hepatobiliary pathway might compensate for reduced/absent elimination via the urinary pathway in the event of compromised renal function, as a possible protective mechanism against nephrogenic systemic fibrosis (NSF). ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirchin, M A, Lorusso, V, Pirovano, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Institute of Radiology. 2015
Materias:	Full Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651256/ https://www.ncbi.nlm.nih.gov/pubmed/25651409 http://dx.doi.org/10.1259/bjr.20140526

Ejemplares similares

Gadobenate dimeglumine (MultiHance) or gadoterat emeglumine (Dotarem) for brain tumour imaging? An intra-individual comparison
por: Vaneckova, M, et al.
Publicado: (2015)

Severe Adverse Drug Reaction to Gadobenate Dimeglumine
por: Singer, Benjamin D., et al.
Publicado: (2009)

The Unusual Suspect: Gadobenate-Dimeglumine Induced Kounis Syndrome
por: Choudhry, Faiza, et al.
Publicado: (2019)

Low-dose gadobenate dimeglumine-enhanced MRI of the kidney for the differential diagnosis of localized renal lesions
por: Schneider, Guenther, et al.
Publicado: (2015)

Comparison of Gadopentetate dimeglumine and Gadobenate dimeglumine in depiction of non-ischemic fibrosis in hypertrophic cardiomyopathy
por: Rudolph, Andre, et al.
Publicado: (2009)

Single dose gadobenate dimeglumine for imaging chronic of myocardial infarction in comparison to double dose gadopentetate dimeglumine
por: Bauner, Kerstin U, et al.
Publicado: (2009)

Dose‐Lowering in Contrast‐Enhanced MRI of the Central Nervous System: A Retrospective, Parallel‐Group Comparison Using Gadobenate Dimeglumine
por: DeLano, Mark C., et al.
Publicado: (2021)

Gadobenate Dimeglumine as an Intrabiliary Contrast Agent: Comparison with Mangafodipir Trisodium with Respect to Non-dilated Biliary Tree Depiction
por: Lim, Joon Seok, et al.
Publicado: (2005)

Nebulized liposomal gadobenate dimeglumine contrast formulation for magnetic resonance imaging of larynx and trachea
por: Wei, Xiaohui, et al.
Publicado: (2011)

Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma
por: Li, Yueming, et al.
Publicado: (2021)

A Comparison between Gadofosveset Trisodium and Gadobenate Dimeglumine for Steady State MRA of the Thoracic Vasculature
por: Camren, G. Paul, et al.
Publicado: (2014)

MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine
por: Brismar, Torkel B., et al.
Publicado: (2011)

Small Brain Lesion Enhancement and Gadolinium Deposition in the Rat Brain: Comparison Between Gadopiclenol and Gadobenate Dimeglumine
por: Violas, Xavier, et al.
Publicado: (2022)

Myocardial T1 mapping and determination of partition coefficients at 3 tesla: comparison between gadobenate dimeglumine and gadofosveset trisodium
por: Nacif, Marcelo Souto, et al.
Publicado: (2018)

Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis
por: Li, Xiu-Mei, et al.
Publicado: (2017)

Single-Dose Gadobutrol in Comparison With Single-Dose Gadobenate Dimeglumine for Magnetic Resonance Imaging of Chronic Myocardial Infarction at 3 T
por: Wildgruber, Moritz, et al.
Publicado: (2014)

Detection of Malignant Primary Hepatic Neoplasms with Gadobenate Dimeglumine (Gd-BOPTA) Enhanced T1-Weighted Hepatocyte Phase MR Imaging: Results of Off-site Blinded Review in a Phase-II Multicenter Trial
por: Peña, Constantino S., et al.
Publicado: (2001)

Use of oral gadobenate dimeglumine to visualise the oesophagus during magnetic resonance angiography in patients with atrial fibrillation prior to catheter ablation
por: Faletti, Riccardo, et al.
Publicado: (2014)

(18) F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine
por: Kirchner, Julian, et al.
Publicado: (2017)

Hypointense Hepatic Lesions Depicted on Gadobenate Dimeglumine-Enhanced Three-Hour Delayed Hepatobiliary-Phase MR Imaging: Differentiation between Benignancy and Malignancy
por: Hwang, Hye Sun, et al.
Publicado: (2009)

Imaging Findings of Hepatic Ewing’s Sarcoma on Computed Tomography and Gadobenate Dimeglumine-enhanced Magnetic Resonance Imaging: A Case Report and Literature Review
por: Lu, Tao, et al.
Publicado: (2022)

MultiHance as a contrast alternative for Gadovist allergic patients
por: Malone, Janna, et al.
Publicado: (2020)

Gadoxetic Acid (Gd-EOB-DTPA)-Enhanced MRI versus Gadobenate Dimeglumine (Gd-BOPTA)-Enhanced MRI for Preoperatively Detecting Hepatocellular Carcinoma: an Initial Experience
por: Park, Yulri, et al.
Publicado: (2010)

Diagnostic Efficacy and Safety of Gadoxetate Disodium vs Gadobenate Dimeglumine in Patients With Known or Suspected Focal Liver Lesions: Results of a Clinical Phase III Study
por: Zech, Christoph J, et al.
Publicado: (2019)

Preoperative radiomics model using gadobenate dimeglumine-enhanced magnetic resonance imaging for predicting β-catenin mutation in patients with hepatocellular carcinoma: A retrospective study
por: Zeng, Fengxia, et al.
Publicado: (2022)

Breast lesion detection and characterization with contrast‐enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T
por: Clauser, Paola, et al.
Publicado: (2018)

A preoperative model based on gadobenate-enhanced MRI for predicting microvascular invasion in hepatocellular carcinomas (≤ 5 cm)
por: Zhang, Sisi, et al.
Publicado: (2022)

Hepatobiliary Phase Features of Preoperative Gadobenate-Enhanced MR can Predict Early Recurrence of Hepatocellular Carcinoma in Patients Who Underwent Anatomical Hepatectomy
por: Liu, Wanmin, et al.
Publicado: (2022)

TI nulling and contrast conditions with a 0.15 mmol/kg dosage of MultiHance as compared to the standard 0.2 mmol/kg gadolinium dosage in patients with myocardial infarcts
por: Yamrozik, June A, et al.
Publicado: (2009)

A greater incidence of nausea/vomiting reactions to Multihance(®) is seen among those of African descent
por: Kissinger, Kraig V, et al.
Publicado: (2015)

Biliary excretion of cadmium.
por: Elinder, C G, et al.
Publicado: (1979)

Nephrogenic Adenoma of the Urinary Bladder: A Review of the Literature
por: Venyo, Anthony Kodzo-Grey
Publicado: (2015)

Neurotoxic Manifestations of an Overdose Intrathecal Injection of Gadopentetate Dimeglumine
por: Park, Kwan-Woong, et al.
Publicado: (2010)

The Pharmacokinetics of The Biliary Excretion of Ciprofloxacin
por: Ball, C. S., et al.
Publicado: (1989)

Metabolomics analysis reveals the differences between Abrus cantoniensis Hance and Abrus mollis Hance
por: Cao, Kexin, et al.
Publicado: (2023)

Postoperative Compensatory Ammonium Excretion Subsequent to Systemic Acidosis in Cardiac Patients
por: Roehrborn, Friederike, et al.
Publicado: (2017)

Studies on biliary excretion of alkaline phosphatase in the rat.
por: Fenster, L. F., et al.
Publicado: (1967)

Nephrogenic systemic fibrosis
por: Braverman, Irwin M, et al.
Publicado: (2010)

Nephrogenic adenoma of the ureter
por: Doluoglu, Omer Gokhan, et al.
Publicado: (2012)

Nephrogenic systemic fibrosis
por: Madke, Bhushan, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1tekp47eqsp4g98mqk91hhsvd1